EFMH
TGTX icon

E Fund Management (HK)’s TG Therapeutics TGTX Stock Holding History

E Fund Management (HK)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Buy
691
+199
+40% +$8.14K 0.01% 213
2026
Q1 		$16.3K Buy
+492
New +$14.7K 0.01% 229

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

E Fund Management (HK)'s TGTX Position: Q2 2026 in Review

E Fund Management (HK) increased its TG Therapeutics (TGTX) stake by 40% in Q2 2026, buying an estimated $8.14K and bringing the position to 691 shares worth $38K. The position accounts for 0.01% of the portfolio, ranked #213.

E Fund Management (HK) first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • E Fund Management (HK) held 691 shares of TG Therapeutics worth $38K as of Q2 2026.
  • E Fund Management (HK) bought 199 TG Therapeutics shares in Q2 2026, an estimated $8.14K.
  • TG Therapeutics made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #213 holding.
  • E Fund Management (HK) first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.